Venlafaxine-induced interstitial lung disease with COVID-19 pandemic-related depression.
Akihito OkazakiKatsunao KitaPublished in: Clinical case reports (2022)
Venlafaxine-associated pulmonary toxicity is rare, with only a few reports of pneumonitis, eosinophilic pneumonia, and asthma. We report a case of venlafaxine-induced interstitial lung disease in a patient with coronavirus disease 2019 pandemic-related depression. Chest imaging findings improved after discontinuation of venlafaxine and treatment with corticosteroids.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- coronavirus disease
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- high glucose
- diabetic rats
- depressive symptoms
- drug induced
- sars cov
- oxidative stress
- pulmonary hypertension
- chronic obstructive pulmonary disease
- emergency department
- high resolution
- sleep quality
- endothelial cells
- physical activity
- photodynamic therapy
- stress induced
- smoking cessation
- cystic fibrosis
- fluorescence imaging
- respiratory failure
- oxide nanoparticles